TMEM106B inhibitors belong to a class of chemical compounds designed to target and modulate the activity of the TMEM106B protein, also known as Transmembrane Protein 106B. TMEM106B is a transmembrane protein found in the membranes of cellular organelles, particularly the lysosome, and it has gained attention for its potential roles in cellular trafficking, membrane dynamics, and lysosomal function. While the exact functions of TMEM106B are still being elucidated, researchers have identified associations between TMEM106B and neurodegenerative diseases, particularly frontotemporal lobar degeneration (FTLD). Inhibitors designed to target TMEM106B are primarily employed in molecular and cellular biology research to investigate the functional properties and regulatory mechanisms associated with this protein.
The development of TMEM106B inhibitors typically involves a combination of biochemical, biophysical, and structural approaches aimed at identifying or designing molecules that can selectively interact with TMEM106B and modulate its activity within cellular organelles like the lysosome. By inhibiting TMEM106B, these compounds can potentially disrupt its functions in intracellular trafficking and lysosomal processes, affecting cellular pathways dependent on proper lysosomal function. Researchers use TMEM106B inhibitors to explore the intricate roles played by this protein in cellular functions, such as protein degradation, membrane trafficking, and lysosomal homeostasis, contributing to our understanding of fundamental cellular mechanisms and providing insights into potential avenues for further scientific exploration.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR which can regulate protein synthesis; may indirectly decrease TMEM106B expression by influencing this pathway. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Causes premature chain termination during translation; could non-specifically reduce TMEM106B levels due to inhibited synthesis. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Specific V-ATPase inhibitor, could alter lysosomal functions and indirectly modulate TMEM106B expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Known to accumulate in lysosomes and could indirectly affect TMEM106B expression by disrupting lysosomal function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Inhibits N-linked glycosylation; might reduce TMEM106B levels due to its role in glycoprotein synthesis. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Inhibits HMG-CoA reductase, affecting cholesterol synthesis; might influence TMEM106B expression indirectly via lipid raft composition. | ||||||
β-Lapachone | 4707-32-8 | sc-200875 sc-200875A | 5 mg 25 mg | $110.00 $450.00 | 8 | |
Activates NQO1, affecting cellular redox states; may indirectly modulate TMEM106B expression. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
Cholesterol transport inhibitor; could alter intracellular cholesterol distribution and affect TMEM106B expression. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
Inhibits neutral sphingomyelinase, potentially affecting lysosomal function and TMEM106B expression. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Inhibits translation initiation; might non-specifically decrease TMEM106B protein synthesis. | ||||||